If you are starting or switching, bring that log to your clinician to help determine how quickly to adjust and which specific mitigation steps to take
GIP:
A medical history review helps determine the most appropriate approach
Here is how many participants in each group hit specific milestones: 10% or more body weight loss: More participants achieved this with tirzepatide 15% or more body weight loss: Substantially more with tirzepatide 20% or more body weight loss: Significantly more with tirzepatide 25% or more body weight loss: 31.6% of tirzepatide users versus only 16.1% of semaglutide users Nearly twice as many people on tirzepatide achieved 25% or greater body weight loss compared to semaglutide
However, like any intravenous treatment, it carries minor risks, including: Temporary nausea or dizziness Allergic reactions (rare) Skin rashes Mild pain at injection site Dr
These lawsuits claim that drug manufacturers like Novo Nordisk and Eli Lilly failed to adequately warn patients about the significant risks, including stomach paralysis, intestinal obstruction, vision loss, and other serious health complications